PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.98%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
13.85%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
55.96%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
34.61%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
52.80%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
58.33%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
58.33%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-4.00%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.80%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.68%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
58.13%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
131.71%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-8.26%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
19.49%
5Y revenue/share CAGR under 50% of AVGO's 122.61%. Michael Burry would suspect a significant competitive gap or product weakness.
74.31%
3Y revenue/share CAGR 1.25-1.5x AVGO's 60.90%. Bruce Berkowitz might see better product or regional expansions than the competitor.
93.48%
10Y OCF/share CAGR under 50% of AVGO's 441.92%. Michael Burry would worry about a persistent underperformance in cash creation.
35.53%
Below 50% of AVGO's 73.80%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
148.63%
3Y OCF/share CAGR above 1.5x AVGO's 34.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
107.17%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-49.18%
Negative 5Y net income/share CAGR while AVGO is 651.30%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
669.14%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
195.47%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-5.11%
Negative 5Y equity/share growth while AVGO is at 147.32%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
17.24%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
63.48%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
26.48%
Below 50% of AVGO's 71.80%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
9.16%
Below 50% of AVGO's 38.29%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
12.15%
AR growth well above AVGO's 14.59%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.45%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.72%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.31%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.22%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.40%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.45%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.